Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,946 DKK | -0.99% | -3.09% | -9.70% |
Apr. 30 | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
Apr. 30 | Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.70% | 18.2B | |
-0.83% | 104B | |
+5.94% | 97.47B | |
+5.71% | 22.25B | |
-13.23% | 21.68B | |
-39.98% | 17.02B | |
-9.89% | 16.36B | |
+8.55% | 14.39B | |
+39.40% | 12.37B | |
+305.91% | 8.43B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab Says Epcoritamab Drug Combination Shows 98% Overall Response Rate in Phase 1/2 Trial in Follicular Lymphoma